Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Keeping Track: HIV Filings Include Novel Agent From Gilead, Viiv's Two-Drug Maintenance Regimen

18 Jun 2017

Keeping Track Feature image

Related Content

Gilead's Bictegravir Demonstrates Broad Non-Inferiority, But Will That Suffice?

30 May 2017

ViiV/Janssen Forge Two-Drug Future For HIV With SWORD Filings

02 Jun 2017

Gilead's Bictegravir Data Could Mean Continued HIV Sector Dominance

16 Feb 2017

ViiV/Janssen's Double-Edged SWORD: Four Drugs Good, Two Drugs Better?

14 Feb 2017

Gilead, With Two PRVs In Hand, Holds Options For Accelerating Late-Stage Pipeline

21 Feb 2017

Related Companies

Gilead Sciences, Inc.

ViiV Healthcare

Merck & Co., Inc.

AbbVie Inc.

Johnson & Johnson

GSK plc

Additional Topics

United States Approvals Regulation Infectious Diseases BioPharmaceutical

More from Approvals

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.